InvestorsHub Logo

Gator328

02/28/23 10:47 AM

#405233 RE: kevindenver #405230

I agree, Kevin. I also believe there will be multiple approaches, just as there are several different drug options to treat a headache (Tylenol, Advil, aspirin, etc). I am more interested in Sigma-1 in the broader context, if this is a new approach to treating illness and Anavex is the pioneer it will bode well for the long-term share price.

Hoskuld

02/28/23 11:08 AM

#405237 RE: kevindenver #405230

I am very suspicious of the lecanemab trial data and analysis: removing AB has been proven over and over not to work so...how did this trial design and execution manage to elicit a tiny but statistically significant signal? I don't think that used broadly it would help at all and suspect that Biogen created an artificially receptive pool of patients to generate what was still a very, very weak signal.